August 12: The Week in Cancer News
Drug for HER2-positive cancer receives further approvals, and researchers study the risk of lung cancer from wildfires.
Progress Against Cancer
Drug for HER2-positive cancer receives further approvals, and researchers study the risk of lung cancer from wildfires.
The FDA granted accelerated approval to the first HER2-targeted therapy for the treatment of non-small cell lung cancer with activating HER2 mutations The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
The FDA approved the kinase inhibitor capmatinib for lung cancers harboring a certain mutation in the protein MET. The U.S. Food and Drug Administration (FDA) has granted full approval to capmatinib (Tabrecta) for the...
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients...
Study finds majority of patients treated with chemotherapy experience hearing loss, and more from this week in cancer news.
The FDA approved darolutamide for the treatment of metastatic prostate cancer that is sensitive to hormone-blocking treatment. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa), in combination with the chemotherapy docetaxel,...
Cancer patients and doctors concerned about how abortion bans will affect treatment, and resistant starch supplements lower risk of many cancers in people with Lynch syndrome.
Clinical outcomes are similar between Black and non-Black patients when patients receive identical treatment and follow-up in a highly structured study environment, researchers say. When Black patients were included in proportion to the larger...
Drug shortages in hematology oncology and more from the week in cancer news, as selected by the editors of Cancer Today magazine.
A new study adds nuance to the ‘golden age’ of cancer drug approvals.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More